Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Atezolizumab With SABR in Metastatic Tumours
NCT02992912Phase 2Completed
- Sponsor
- Gustave Roussy
- Start
- Nov 2016
- Primary completion
- May 2022
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of atezolizumab in colorectal cancer (CRC), non-small cell lung cancer (NSCLC), renal cell carcinoma (RCC), sarcoma, sponsored by Gustave Roussy. Started Nov 2016; status: completed.
02
Drugs
atezolizumab
03
Conditions
colorectal cancer (CRC)non-small cell lung cancer (NSCLC)renal cell carcinoma (RCC)sarcoma
Beyond the preview
Go deeper on NCT02992912.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02992912.